Dr Anna Dorothea Wagner speaks to ecancer about the overall survival results of the EORTC-1203 GITC "INNOVATION" trial.

This trial investigates perioperative treatment for HER2-positive gastric cancer, emphasising trastuzumab's role in enhancing response rates and survival.

The trial features three treatment arms and incorporates the FLOT chemotherapy regimen.

Results indicate improved major pathologic response rates with trastuzumab, though toxicity affects chemotherapy dosing.

While survival benefits are not statistically significant, the study highlights the importance of funding and the clinical relevance of trastuzumab for surgical candidates.